The financial results for the first quarter of fiscal year 2025 were generally positive, with significant increases in revenue and profit metrics. The HIV business showed strong growth, and strategic M&A activities were completed successfully. However, there were challenges in domestic and overseas business performance, especially in China, and a noted decrease in R&D spending. Overall, the positive aspects of financial growth and strategic developments outweigh the challenges.

Company Guidance -

Q2 2025

In the first quarter of fiscal year 2025, SHIONOGI & Co., Ltd. reported a strong financial performance with revenue reaching JPY99.8 billion, marking an increase of JPY2.2 billion compared to the same period last year. Operating profit rose by JPY7 billion to JPY35.1 billion, while profit before tax increased by JPY9.8 billion, reaching JPY46.3 billion. Profit attributable to owners of the parent was JPY39.4 billion, up JPY8.7 billion, and EBITDA grew by JPY7 billion to JPY40.6 billion. The company noted that the HIV business, especially through partnerships with ViiV, showed strong growth, contributing significantly to royalty income, which rose to JPY63.9 billion. SHIONOGI also highlighted progress in its development pipelines, including the filing of Ensitrelvir in Europe and the U.S., and emphasized its ongoing efforts in cost management and strategic investments to sustain growth. Additionally, the company completed a tender offer for Torii Pharmaceutical and made strides in acquiring the pharmaceutical business of JT Group, positioning it for future expansion.

Strong Financial Performance

Revenue increased to JPY99.8 billion, up JPY2.2 billion YoY. Operating profit rose to JPY35.1 billion, up JPY7 billion YoY. Profit before tax reached JPY46.3 billion, an increase of JPY9.8 billion YoY. EBITDA was JPY40.6 billion, up JPY7 billion from the previous year.

HIV Business Growth

The HIV business experienced accelerated growth, contributing significantly to overall revenue. Strong sales from products like Cabenuva, Apretude, and Dovato are driving this growth.

Successful M&A and Pipeline Developments

Completion of the tender offer for Torii Pharmaceutical and progress in the merger with JT Group's pharmaceutical business. Development of Ensitrelvir in Europe and the U.S. is progressing, with applications for approval submitted.

Royalties and Global Expansion

Royalty income increased to JPY63.9 billion, up JPY2.9 billion YoY, driven by ViiV's strong HIV sales and Roche's Xofluza sales. Expansion of Fetroja and Fetcroja in Europe and the U.S. contributed to revenue growth.

Shionogi & Co (SGIOF) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SGIOF Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 27, 2025	2025 (Q2)	0.36 / -	0.419	―	―	―
Jul 28, 2025	2025 (Q1)	0.28 / 0.31	0.244	28.42% (+0.07)		―
May 12, 2025	2024 (Q4)	0.33 / 0.29	0.277	5.35% (+0.01)		―
Jan 31, 2025	2024 (Q3)	0.31 / 0.40	0.288	40.43% (+0.12)		―
Oct 28, 2024	2024 (Q2)	0.32 / 0.42	0.371	12.88% (+0.05)		―
Jul 29, 2024	2024 (Q1)	0.27 / 0.24	0.327	-25.27% (-0.08)		―
May 13, 2024	2023 (Q4)	0.29 / 0.28	0.164	69.16% (+0.11)		―
Jan 31, 2024	2023 (Q3)	0.44 / 0.29	0.764	-62.31% (-0.48)		―
Oct 31, 2023	2023 (Q2)	0.27 / 0.37	0.17	118.59% (+0.20)		―
Jul 31, 2023	2023 (Q1)	0.34 / 0.33	0.26	25.57% (+0.07)		―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SGIOF Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 28, 2025	$16.81	$17.60	+4.70%
May 12, 2025	$15.20	$15.20	0.00%
Jan 31, 2025	$14.62	$15.40	+5.34%
Oct 28, 2024	$13.55	$13.61	+0.44%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Shionogi & Co (SGIOF) report earnings?

Shionogi & Co (SGIOF) is schdueled to report earning on Oct 27, 2025, TBA (Confirmed).

What is Shionogi & Co (SGIOF) earnings time?

Shionogi & Co (SGIOF) earnings time is at Oct 27, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is SGIOF EPS forecast?

SGIOF EPS forecast for the fiscal quarter 2025 (Q2) is 0.36.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing